istock-659112420_kate_sept2004

kate_sept2004 / iStockphoto.com

26 October 2018Americas

Generic competition: when one door closes, another opens

For consumers, the prospect of drugs going off-patent may well be a blessing. But for the pharmaceutical companies behind the branded medication, the onslaught of generic competition is seemingly far from positive.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

Broad Institute wins appeal to restore CRISPR patent in Europe